Epidermolysis bullosa and the COVID-19 pandemic: challenges and recommendations

J Dermatolog Treat. 2022 Mar;33(2):1178-1179. doi: 10.1080/09546634.2020.1788701. Epub 2020 Jul 26.

Authors

Hassan Vahidnezhad^{1

2}, Hamideh Moravvej³, Ayda Bahmanjahromi³, Leila Youssefian^{1

2}, Fahimeh Abdollahimajd^{3

4}

Affiliations

¹ Department of Dermatology and Cutaneous Biology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA.
² Jefferson Institute of Molecular Medicine, Thomas Jefferson University, Philadelphia, PA, USA.
³ Skin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
⁴ Clinical Research Development Unit, Shohada-e Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

PMID: 32589062
DOI: 10.1080/09546634.2020.1788701

No abstract available

Publication types

Letter

MeSH terms

COVID-19*
Epidermolysis Bullosa Dystrophica*
Epidermolysis Bullosa*
Humans
Pandemics